984 RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND STUDY
2024 · Gastroenterology · 1 citations
https://doi.org/10.1016/s0016-5085(24)01033-3
W
W Rachel Duan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
10
Papers
5
Citations
2
h-index
0
i10-index
W Rachel Duan is an academic researcher from Yanshan University. The author has contributed to research in topics: Inflammatory Bowel Disease & Immunodeficiency and Autoimmune Disorders & Tuberculosis Research and Epidemiology. The author has an h-index of 2, co-authored 9 publications.
Papers by this author
worksSu1761 EFFICACY AND SAFETY UP TO THREE YEARS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE FORTIFY OPEN-LABEL LONG-TERM EXTENSION
2024 · Gastroenterology · 0 citations
https://doi.org/10.1016/s0016-5085(24)02325-4
ZIF‐Derived Co@Fe‐P Electrocatalyst With Core‐Shell Structure for Efficient Oxygen Evolution Reaction
2025 · Carbon Energy · 0 citations
https://doi.org/10.1002/cey2.70095
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat